Q-omics provides the consensus-scored L1CAM profile across patient tissues and cancer cell-line models. L1CAM expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, L1CAM is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, L1CAM protein abundance shows 24,170 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where L1CAM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for L1CAM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes L1CAM survival associations across molecular data types. L1CAM RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible L1CAM RNA expression–survival associations across cancer types. High L1CAM expression shows unfavorable associations in KIRC, MESO, BRCA, UCEC, ACC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for L1CAM RNA expression.
This table summarizes L1CAM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for L1CAM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. L1CAM shows lower tumor expression in KIRC, COAD, KICH, BLCA and LIHC and higher tumor expression in HNSC. The KIRC box plot shows higher L1CAM RNA expression in normal versus tumor tissue (log2 FC = −4.497, t-test p < 0.001).
This table shows molecular features associated with L1CAM in patient tissues and cancer cell lines. In patient samples, L1CAM shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, L1CAM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
